Physician profile
Ginger L Leon
NPI 1245234780
$2,141.27
in general payments reported to CMS, 2019-2025
17 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $448 · 2021: $329 · 2022: $176 · 2023: $317 · 2024: $131 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,064.13 | 2019-2025 | Wegovy, Ozempic |
| Amgen INC. | $215.81 | 2021-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.97 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $102.85 | 2020-2024 | Zepbound, Emgality, Jardiance |
| Astellas Pharma US INC | $94.54 | 2019-2024 | Veozah |
| Abbott Laboratories | $78.61 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $58.77 | 2019-2020 | |
| Hologic Sales and Service, LLC | $47.09 | 2023-2025 | Aptima |
| Currax Pharmaceuticals LLC | $42.75 | 2020 | |
| Bard Peripheral Vascular, INC. | $42.55 | 2021 | |
| Exact Sciences Corporation | $39.90 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $39.16 | 2025 | Breztri, Airsupra |
| Dexcom, INC. | $37.72 | 2022-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $31.11 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.38 | 2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.22 | 2023 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.71 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.